undefined - HealthTree for AML

HealthTree Podcast for AML

This program consists of one-hour podcast episodes where we interview top AML researchers on their open clinical trials and other key AML news topics.

Each article will include background information on the AML researcher, a summary of the radio show, the full radio recording so you can listen to the entire show whenever you want, and a written transcript in case you would rather read the interview.

This podcast is great for AML patients who are interested in learning about the most cutting-edge AML research. These shows go beyond the basic question of "what is AML" and really explain all the ins and outs of AML in great detail. By listening, you are able to learn about which AML research trials you may be able to participate in. Be on the lookout for announcements on our upcoming episodes so that you can mark your calendar and listen live!

Podcast: Digging Deeper Into the TP53 Mutation in AML with Dr. Rory Shallis, Yale New Haven

July 15, 2022

Listen to the recording of our conversation with Dr. Rory Shallis, an AML expert, who discusses the TP53 mutation in AML.

Podcast: Weighing FLT3 Inhibitor Options with Dr. Jane Liesveld, University of Rochester

June 28, 2022

Listen to the recording of our podcast with Dr. Jane Liesveld, an AML expert, about the different FLT3 options available for treatment and in development .

Podcast: Attacking AML Cells with a New Immunotherapy Infusion with Dr. Kendra Sweet

June 09, 2022

Listen to the full recording of our conversation with Dr. Kendra Sweet, an AML expert, about a new antibody drug conjugate in development called IMGN632.

Podcast: Killing AML Cells with Magrolimab, a New Immunotherapy Option, with Dr. Joseph Jurcic

May 26, 2022

Listen to the full recording of our conversation with Dr. Joseph Jurcic, an AML expert, about a new immunotherapy drug in development called magrolimab.

Full Radio Show: Targeting FLT3 Positive AML with New & Improved Therapies with Dr. Margaret Kasner

February 28, 2022

Listen to the full recording (or read the transcript) of our conversation with Dr. Margaret Kasner, an AML expert from Sidney Kimmel Cancer Center as she summarizes key developments and clinical trials currently underway for FLT3 positive AML.

Full Radio Show: AML Progress in 2021 and a Look to the Future with Dr. Eytan Stein

February 18, 2022

Listen to the full recording (or read the transcript) of our conversation with Dr. Eytan Stein, an AML expert from Memorial Sloan Kettering Cancer Center as he shares his top abstracts of 2021 that were presented by himself and his AML colleagues at the 2021 ASH conference and provides us his thoughts on what AML advancements and research to look out for in 2022.

Full Radio Show: The Latest in AML Treatment Advances: Where We Are and Where We're Going with James Blachly, MD, Ohio State University

October 25, 2021

Listen to the full recording of our conversation with Dr. James Blachly, an AML expert from Ohio State University as he provides a comprehensive overview of newer AML treatments and discusses their use in clinics and hospitals today. Additionally, he shares an overview of the promising agents currently under development along with information on key clinical trials taking place that will further shape the future of AML treatment.

Full Radio Show: Harnessing the Immune System in Relapsed/Refractory AML with Dr. John Reagan, Rhode Island Hospital

October 01, 2021

Listen to the full recording of our conversation with Dr. John Reagan, an AML expert from the Lifespan Cancer Institute at Rhode Island Hospital as he discusses relapsed and refractory AML. He reviews how immunotherapy is a promising area of AML research and discusses his open clinical trial looking at the combination of gemtuzumab and donor leukocyte infusion.

Full Radio Show: The Advancement of Treatment Options for Older Adults with AML with Gabriel Mannis, MD, Stanford Cancer Institute

September 20, 2021

Listen to the full recording of our conversation with Dr. Gabriel Mannis, an AML expert from the Stanford Cancer Institute in California about how hypomethylating agents and venetoclax have become the new standard of care for older individuals with AML and his open clinical trial looking at what could become the first all oral therapy for newly diagnosed AML.